Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab, to Demonstrate Efficacy After Twelve Weeks of Treatment and to Assess Safety, Tolerability and Long-term Efficacy up to One Year in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis With or Without Psoriatic Arthritis Comorbidity
Brief Summary: The purpose of this study was to determine if secukinumab is effective and safe in the treatment of plaque type psoriasis


Options:
A: Arm Label: Active Treatment 10 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: ActiveTreatment 5 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Placebo Treatment; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo/CP-690,550 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Active Treatment 10 mg BID | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): ActiveTreatment 5 mg BID | Intervention Type: DRUG; Name: Placebo/CP-690,550; Assigned to Arm(s): Placebo Treatment | Intervention Type: DRUG; Name: Placebo/CP-690,550; Assigned to Arm(s): Placebo Treatment
B: Arm Label: Secukinumab 150mg; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab 150 mg s.c. | Arm Label: Secukinumab 300mg; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab 300 mg s.c. | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Secukinumab 150 mg s.c.; Assigned to Arm(s): Secukinumab 150mg | Intervention Type: DRUG; Name: Secukinumab 300 mg s.c.; Assigned to Arm(s): Secukinumab 300mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Placebo 2 mL auto-injector; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo 2 mL auto-injector | Arm Label: Placebo 1 mL prefilled syringe; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo 1 mL prefilled syringe | Arm Label: Secukinumab 2 mL auto-injector; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab 2 mL auto-injector | Arm Label: Secukinumab 1 mL prefilled syringe; Type: ACTIVE_COMPARATOR; Interventions: Drug: Secukinumab 1 mL prefilled syringe | Intervention Type: DRUG; Name: Placebo 2 mL auto-injector; Assigned to Arm(s): Placebo 2 mL auto-injector | Intervention Type: DRUG; Name: Placebo 1 mL prefilled syringe; Assigned to Arm(s): Placebo 1 mL prefilled syringe | Intervention Type: DRUG; Name: Secukinumab 2 mL auto-injector; Assigned to Arm(s): Secukinumab 2 mL auto-injector | Intervention Type: DRUG; Name: Secukinumab 1 mL prefilled syringe; Assigned to Arm(s): Secukinumab 1 mL prefilled syringe
D: Arm Label: Cohort 1; Type: EXPERIMENTAL; Interventions: Drug: (CP-6890,550) Tofacitinib, Drug: Placebo | Arm Label: Cohort 2; Type: EXPERIMENTAL; Interventions: Drug: (CP-690,550) Tofacitinib, Drug: Placebo | Intervention Type: DRUG; Name: (CP-6890,550) Tofacitinib; Assigned to Arm(s): Cohort 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1 | Intervention Type: DRUG; Name: (CP-690,550) Tofacitinib; Assigned to Arm(s): Cohort 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 2

Answer: B